ABIG Health and JD Lymon Group join forces on device commercialization

ABIG Health and JD Lymon Group announced a strategic affiliation on November 4, 2026, to give medtech and health technology companies one team for regulatory, reimbursement, market access and commercialization strategy. The partners said the goal is to reduce duplicated work and align FDA decisions with payer coverage and adoption from the start.

Why it matters: - Medical device and health tech companies often lose time and money when regulatory, reimbursement and market access advice comes from separate firms. - The affiliation is meant to align FDA strategy with coverage, coding, payment and adoption planning from the first study design. - The goal is to help emerging companies move from clearance to real-world revenue with fewer vendor handoffs and less rework.

What happened: - ABIG Health and JD Lymon Group announced a strategic affiliation on November 4, 2026. - The partnership combines two teams of senior healthcare executives. - The firms said clients can now access one coordinated team across the full product lifecycle. - The affiliation targets medical device and health technology innovators in the U.S. market.

The details: - The combined offering covers clinical scenario and market strategy, evidence planning, regulatory strategy, reimbursement, market access and launch, and adoption, engagement and growth. - Evidence planning is intended to support FDA, CMS, commercial payers and clinicians at the same time. - Regulatory pathway decisions are meant to be tested against reimbursement impact before studies move forward. - Reimbursement support includes coding, coverage and payment strategy. - Market access support includes payer engagement, value story and commercialization. - ADoption support includes clinician uptake and business strategy. - ABIG Health describes its role as a strategic commercialization partner for health tech, digital health and medtech companies. - ABIG Health says it helps clients navigate FDA pathways, CMS and payer reimbursement, clinical feasibility and go-to-market strategy. - JD Lymon Group describes itself as a specialized market access consulting firm for medical technology and biopharmaceutical companies. - JD Lymon Group says its partners bring more than 125 years of combined medtech experience across industry, payers and government. - ABIG Health’s leadership includes Steven Farmer, MD, PhD, a former CMS Chief Strategy Officer for coverage determinations, and Adam Brown, MD, MBA, a physician, healthcare executive and business school professor. - JD Lymon Group’s partners include Jolayne Devers, Carla Monacelli, Mark Domyahn, John McInnes and Amanda Cassidy. - The company site links are ABIG Health and JD Lymon Group. - ABIG Health also shared a LinkedIn page at its company profile.

Between the lines: - The announcement reflects a broader medtech pain point: decisions made for FDA clearance can weaken a later reimbursement case if they are not aligned early. - The affiliation is also a response to fragmented vendor models that can force startups to manage multiple contracts and onboarding cycles. - The companies are positioning the partnership around capital efficiency, faster coordination and a single strategy for payers, clinicians and investors.

What's next: - ABIG Health and JD Lymon Group will likely market the affiliation to emerging companies that need coordinated regulatory and market access support. - The value proposition will hinge on whether one integrated team can reduce delays between study design, authorization and adoption. - Both firms are expected to use the affiliation to deepen client work across commercialization and payer strategy.

The bottom line: - ABIG Health and JD Lymon Group are betting that medtech innovators want one strategy from FDA pathway to reimbursement and launch, not a patchwork of disconnected advisors.